Exploring the Immunological Profile in Breast Cancer: Recent Advances in Diagnosis and Prognosis through Circulating Tumor Cells DOI Open Access

Amalia Kotsifaki,

Sousanna Maroulaki,

Athanasios Armakolas

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(9), P. 4832 - 4832

Published: April 29, 2024

This review offers a comprehensive exploration of the intricate immunological landscape breast cancer (BC), focusing on recent advances in diagnosis and prognosis through analysis circulating tumor cells (CTCs). Positioned within broader context BC research, it underscores pivotal role immune system shaping disease’s progression. The primary objective this investigation is to synthesize current knowledge aspects BC, with particular emphasis diagnostic prognostic potential offered by CTCs. adopts thorough examination relevant literature, incorporating breakthroughs field. methodology section succinctly outlines approach, specific focus CTC its implications for prognosis. Through review, insights into dynamic interplay between are highlighted, CTCs advancing methodologies refining assessments. Furthermore, presents substantiated results, contributing deeper understanding complexity BC. In conclusion, significance exploring profile patients, providing valuable novel utilization presentation findings emphasizes crucial dynamics, thereby opening avenues enhanced clinical management strategies.

Language: Английский

The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth DOI Creative Commons
Karin E. de Visser, Johanna A. Joyce

Cancer Cell, Journal Year: 2023, Volume and Issue: 41(3), P. 374 - 403

Published: March 1, 2023

Language: Английский

Citations

1539
Metastasis DOI Creative Commons

Stefanie Gerstberger,

Qingwen Jiang, Karuna Ganesh

et al.

Cell, Journal Year: 2023, Volume and Issue: 186(8), P. 1564 - 1579

Published: April 1, 2023

Language: Английский

Citations

357
New insights into the correlations between circulating tumor cells and target organ metastasis DOI Creative Commons

Qinru Zhan,

Bixia Liu,

Xiaohua Situ

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: Dec. 21, 2023

Organ-specific metastasis is the primary cause of cancer patient death. The distant tumor cells to specific organs depends on both intrinsic characteristics and extrinsic factors in their microenvironment. During an intermediate stage metastasis, circulating (CTCs) are released into bloodstream from metastatic tumors. CTCs harboring aggressive or features can extravasate remote sites for continuous colonizing growth, leading further lesions. In past decade, numerous studies demonstrated that exhibited huge clinical value including predicting assessing prognosis monitoring treatment response et al. Furthermore, increasingly experiments dedicated identifying key molecules inside exploring how they mediate CTC-related organ-specific metastasis. Based above molecules, more inhibitors being developed target utilized completely clean CTCs, which should provide promising prospects administer advanced tumor. Recently, application various nanomaterials microfluidic technologies enrichment technology has assisted improve our deep insights phenotypic biological functions as a potential therapy target, may pave way us make practical strategies. present review, we mainly focus role involved targeted organ especially latest molecular mechanism research intervention strategies related CTCs.

Language: Английский

Citations

54
Circulating tumor cells: from new biological insights to clinical practice DOI Creative Commons
Xuyu Gu, Shiyou Wei,

Xin Lv

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: Sept. 2, 2024

Abstract The primary reason for high mortality rates among cancer patients is metastasis, where tumor cells migrate through the bloodstream from original site to other parts of body. Recent advancements in technology have significantly enhanced our comprehension mechanisms behind bloodborne spread circulating (CTCs). One critical process, DNA methylation, regulates gene expression and chromosome stability, thus maintaining dynamic equilibrium Global hypomethylation locus-specific hypermethylation are examples changes methylation patterns that pivotal carcinogenesis. This comprehensive review first provides an overview various processes contribute formation CTCs, including epithelial-mesenchymal transition (EMT), immune surveillance, colonization. We then conduct in-depth analysis how modifications within CTCs impact each these stages during CTC dissemination. Furthermore, we explored potential clinical implications with cancer. By understanding epigenetic modifications, can gain insights into metastatic process identify new biomarkers early detection, prognosis, targeted therapies. aims bridge gap between basic research application, highlighting significance context metastasis offering avenues improving patient outcomes.

Language: Английский

Citations

29
Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy DOI Creative Commons
Xiaoling Wang, Lijuan Wang,

Haihong Lin

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Jan. 25, 2024

Circulating tumor cells (CTCs), circulating DNA (ctDNA), and extracellular vehicles (EVs) have received significant attention in recent times as emerging biomarkers subjects of transformational studies. The three main branches liquid biopsy evolved from the primary detection targets—CTC, ctDNA, EVs—each with distinct benefits. CTCs are derived cancer original or metastases may display global features tumor. ctDNA has been extensively analyzed used to aid diagnosis, treatment, prognosis neoplastic diseases. EVs contain tumor-derived material such DNA, RNA, proteins, lipids, sugar structures, metabolites. provide different contents but strong complementarity a certain extent. Even though they already employed several clinical trials, utility is still being studied, promising initial findings. This review thoroughly overviews established technologies for isolation, characterization, content CTC, EVs. Also discussed were most developments study potential therapeutic monitoring, prediction. These included Finally, challenges employing based on precision medicine evaluated.

Language: Английский

Citations

27
Pre-metastatic niche: formation, characteristics and therapeutic implication DOI Creative Commons
Yuhang Wang,

Jiachi Jia,

Fuqi Wang

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: Sept. 25, 2024

Language: Английский

Citations

22
Circulating tumor cells as liquid biopsy markers in cancer patients DOI Creative Commons
Daniel J. Smit, Klaus Pantel

Molecular Aspects of Medicine, Journal Year: 2024, Volume and Issue: 96, P. 101258 - 101258

Published: Feb. 21, 2024

Over the past decade, novel methods for enrichment and identification of cancer cells circulating in blood have been established. Blood-based detection other tumor-associated products can be summarized under term Liquid Biopsy. Circulating tumor (CTCs) used diagnosis, risk stratification treatment selection as well monitoring several studies over years, thus representing a valuable biomarker patients. A plethora to enrich, detect analyze CTCs has In contrast liquid biopsy analytes (e.g. ctDNA), represent viable analyte that provides unique opportunity understand underlaying biology metastatic cascade on molecular level. this review, we provide an overview current enrichment, detection, functional characterization CTCs.

Language: Английский

Citations

19
tRNA-derived small RNAs in human cancers: roles, mechanisms, and clinical application DOI Creative Commons

Manli Zhou,

Xiaoyun He, Jing Zhang

et al.

Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)

Published: April 15, 2024

Abstract Transfer RNA (tRNA)-derived small RNAs (tsRNAs) are a new type of non-coding (ncRNAs) produced by the specific cleavage precursor or mature tRNAs. tsRNAs involved in various basic biological processes such as epigenetic, transcriptional, post-transcriptional, and translation regulation, thereby affecting occurrence development human diseases, including cancers. Recent studies have shown that play an important role tumorigenesis regulating behaviors malignant proliferation, invasion metastasis, angiogenesis, immune response, tumor resistance, metabolism reprogramming. These may be potential targets for treatment. Furthermore, can exist abundantly stably bodily fluids (e.g., blood, serum, urine) form free encapsulated extracellular vesicles, intercellular communication microenvironment (TME). Meanwhile, their abnormal expression is closely related to clinicopathological features patients, staging, lymph node poor prognosis patients; thus, served novel liquid biopsy biomarker. This review summarizes discovery, production, analyzes molecular mechanisms applications therapy, which provide strategies early diagnosis targeted therapy tumors.

Language: Английский

Citations

19
Aggregation-Induced Emission Luminogen: Role in Biopsy for Precision Medicine DOI Creative Commons
Yanhong Duo, Lei Han, Yaoqiang Yang

et al.

Chemical Reviews, Journal Year: 2024, Volume and Issue: 124(20), P. 11242 - 11347

Published: Oct. 9, 2024

Biopsy, including tissue and liquid biopsy, offers comprehensive real-time physiological pathological information for disease detection, diagnosis, monitoring. Fluorescent probes are frequently selected to obtain adequate on processes in a rapid minimally invasive manner based their advantages biopsy. However, conventional fluorescent have been found show aggregation-caused quenching (ACQ) properties, impeding greater progresses this area. Since the discovery of aggregation-induced emission luminogen (AIEgen) promoted advancements molecular bionanomaterials owing unique high quantum yield (QY) signal-to-noise ratio (SNR),

Language: Английский

Citations

18
Digoxin for reduction of circulating tumor cell cluster size in metastatic breast cancer: a proof-of-concept trial DOI Creative Commons
Christian Kurzeder, Bich Doan Nguyen-Sträuli,

Ilona Krol

et al.

Nature Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 24, 2025

Abstract The presence of circulating tumor cell (CTC) clusters is associated with disease progression and reduced survival in a variety cancer types. In breast cancer, preclinical studies showed that inhibitors the Na + /K ATPase suppress CTC block metastasis. Here we conducted prospective, open-label, proof-of-concept study women metastatic where primary objective was to determine whether treatment inhibitor digoxin could reduce mean cluster size. An analysis nine patients treated daily maintenance dose (0.7–1.4 ng ml −1 serum level) revealed size reduction −2.2 cells per upon ( P = 0.003), meeting endpoint study. Mechanistically, transcriptome profiling CTCs highlighted downregulation cell–cell adhesion cell-cycle-related genes digoxin, line its cluster-dissolution activity. No treatment-related adverse events occurred. Thus, our data provide first-in-human proof principle leads partial dissolution, encouraging larger follow-up refined include clinical outcome endpoints. ClinicalTrials.gov identifier: NCT03928210 .

Language: Английский

Citations

2